W. Elias

发表

Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting.

David K Howse, A. Verier, M. Valis, 2018, Multiple sclerosis and related disorders.

[MS registry in Germany--design and first results of the pilot phase].

M. Daumer, P. Rieckmann, U. Zettl, 2005, Der Nervenarzt.

Symptomatology of MS: results from the German MS Registry

P. Rieckmann, U. Zettl, S. Schimrigk, 2009, Journal of Neurology.

Multiple sclerosis registry in Germany: results of the extension phase 2005/2006.

P. Rieckmann, U. Zettl, S. Schimrigk, 2008, Deutsches Arzteblatt international.

Costs and quality of life of multiple sclerosis in Germany

G. Kobelt, V. Limmroth, N. König, 2006, The European Journal of Health Economics.

Multiple Sclerosis Registry in Germany

P. Rieckmann, U. Zettl, S. Schimrigk, 2008 .

Quality Assessment in Multiple Sclerosis Therapy (QUASIMS)

J. Hasford, N. Putzki, U. Zettl, 2007, Journal of Neurology.

Escalating immunotherapy of multiple sclerosis--new aspects and practical application.

K. Hess, A. Gass, L. Kappos, 2004, Journal of neurology.

Quality Assessment in Multiple Sclerosis Therapy (QUASIMS): a comparison of interferon beta therapies for relapsing-remitting multiple sclerosis.

J. Hasford, N. Putzki, U. Zettl, 2007, Journal of neurology.

Current issues in immunomodulatory treatment of multiple sclerosis

A. Gass, R. Gold, U. Zettl, 2006, Journal of Neurology.